Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1995-09-29
1999-11-23
Scheiner, Toni R.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
435 723, 435 721, 436 63, 436 64, 436813, G01N 33574, C12Q 168
Patent
active
059898119
ABSTRACT:
A method for screening individuals at risk for the loss of organ confinement in prostate cancer is disclosed. The method is useful for evaluating cells from patients at risk for recurrence of prostate cancer following surgery for prostate cancer. Specifically, the method uses specific Markovian nuclear texture features, alone or in combination with other biomarkers, to determine whether the cancer will progress or lose organ confinement. In addition, methods of predicting the development of fatal metastatic disease by statistical analysis of selected biomarkers is also disclosed. The invention also contemplates a method that uses a neural network to analyze and interpret cell morphology data. Utilizing Markovian factors and other biomarkers as parameters, the network is first trained with a sets of cell data from known progressors and known non-progressors. The trained network is then used to predict the loss of organ confinement by evaluating patient samples.
REFERENCES:
Ackerman et al., "Analysis of Risk Factors Associated with Prostate Cancer Extension to the Surgical Margin and Pelvic Node Metastasis at Radical Prostatectomy", The Journal of Urology, 150:1845-1850, 1993.
Bacus et al., "Prostate Adenocarcinoma--An Image-Analysis Technique for DNA Ploidy Determination", Laboratory Medicine, 24(4):225-231, 1993.
Badalament et al., "DNA Ploidy and Prostate-Specific Antigen as Prognostic Factors in Clinically Resectable Prostate Cancer", Cancer, 67:3014-3023, 1991.
Donald F. Gleason, MD, PhD, "Histologic Grading of Prostate Cancer: A Perspective", Human Pathology, 23(3):273-279, 1992.
Hammerer et al., "Digital Rectal Examination, Imaging, and Systematic-Sextant Biopsy in Identifying Operable Lymph Node-Negative Prostatic Carcinoma", Eur Urol, 22:281-287, 1992.
Katz et al., "Molecular Staging of Prostate Cancer with the Use of an Enhanced Reverse Transcriptase-PCR Assay", Urology, 43(6):765-775, 1994.
Miller et al., "A Multivariate Statistical Algorithm foir Predicting Organ-Confined Disease Status Based Upon the Sextant Biopsy Pathology, PSA and Quantitative Image Analysis", UroCor, Western Section AUA 71st Annual Meeting, Nov. 5-9, 1995, Scottsdale, AZ.
Ravery et al., "Systematic Biopsies Accurately Predict Extracapsular Extension of Prostate Cancer and Persistent/Recurrent Detectable PSA After Radical Prostatectomy", Urology, 44:371-376, 1994.
Terris et al., "Prediction of Prostate Cancer Volume Using Prostate-Specific Antigen Levels, Transrectal Ultrasound, and Systematic Sextant Biopsies", Urology, 45:75-80, 1995.
Ross et al., Cancer, vol. 72, pp. 3020-3028, Nov. 15, 1993.
Partin et al., Cancer, vol. 70, No. 1, pp. 161-168, 1992.
Dawson et al., Anal. Quant. Cytol. Histol., vol. 15, No. 4, pp. 227-235, Aug. 1993.
Molnar, et al., Anal. Cell Pathol., vol. 5, No. 3, pp. 161-175, May 1993.
Ashenayi Kaveh
Bacus Michael P.
Miller M. Craig
Veltri Robert W.
Scheiner Toni R.
Urocor Inc.
LandOfFree
Sextant core biopsy predictive mechanism for non-organ confined does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sextant core biopsy predictive mechanism for non-organ confined , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sextant core biopsy predictive mechanism for non-organ confined will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1220103